Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

News

 

 

Terumo Establishes New Group Identity Institutes "Core Values" to be Shared by All Associateshttps://www.terumo-europe.com/en-emea/news/terumo-establishes-new-group-identity-institutes-core-values-to-be-shared-by-all-associatesTerumo Establishes New Group Identity Institutes "Core Values" to be Shared by All AssociatesTokyo, Japan31/03/2019 22:00:00
Terumo Pharmaceutical Solutions wins 2019 Asia-Pacific Industry Awardhttps://www.terumo-europe.com/en-emea/news/terumo-pharmaceutical-solutions-wins-asia-pacific-industry-awardTerumo Pharmaceutical Solutions wins 2019 Asia-Pacific Industry AwardTokyo, Japan27/02/2019 23:00:00
Terumo Introduces Its Smallest, Lowest Prime Volume, Full-Size Adult* Capiox® Oxygenatorhttps://www.terumo-europe.com/en-emea/news/terumo-introduces-its-smallest-lowest-prime-volume-full-size-adult-capiox®-oxygenatorTerumo Introduces Its Smallest, Lowest Prime Volume, Full-Size Adult* Capiox® OxygenatorAnn Arbor, MICH.16/01/2019 23:00:00<p>​<span>Innovative technology improves patient care during cardiopulmonary bypass</span></p>
Major study investigating abbreviated DAPT post-Ultimaster DES in high bleeding risk patients reaches half-way markhttps://www.terumo-europe.com/en-emea/news/major-study-investigating-abbreviated-dapt-post-ultimaster-des-in-high-bleeding-risk-patients-reaches-half-way-markMajor study investigating abbreviated DAPT post-Ultimaster DES in high bleeding risk patients reaches half-way markLeuven, Belgium09/01/2019 23:00:00<p style="text-align:left;">​<em>Significant milestone achieved for global study likely to change DAPT guidelines</em></p><p style="text-align:justify;">December marked a significant milestone for a landmark study into the use of short duration dual anti-platelet therapy (DAPT) in HBR patients following stenting procedures, with patient recruitment reaching the half-way point.</p>
QuiremScout™, the first and only product indicated for SIRT work-up, receives CE markhttps://www.terumo-europe.com/en-emea/news/quiremscout™-the-first-and-only-product-indicated-for-sirt-work-up-receives-ce-markQuiremScout™, the first and only product indicated for SIRT work-up, receives CE markLeuven, Belgium06/01/2019 23:00:00<p>​Terumo Europe today announced that QuiremScout™ has received CE mark, making it available for clinical centers throughout Europe. QuiremScout™ is designed to advance the SIRT work-up procedure. It does this by improving the accuracy of predicting lung shunting<sup>1</sup> and the intrahepatic distribution<sup>2</sup>, which aims to optimize SIRT patient selection and treatment planning. QuiremScout™ has been developed by Quirem Medical and will be exclusively distributed by Terumo.</p>